✨ Free AI Report
Nanobiotix S.A.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Nanobiotix S.A.
Company Research

Nanobiotix S.A.: Business Overview, Financials & Competitive Analysis

Nanobiotix S.A. scores 7/10 on the AskCyborg Cyborg Score (Strong). Nanobiotix is a physics-based cancer nanotherapy company with differentiated NBTXR3 in partnership with J&J, multiple 2026 clinical catalysts, and strengthened balance sheet positioning. Nanobiotix has a market cap of $1.502B with revenue of $10.16M (trailing twelve months) and cash position of $28.82M as of February 27, 2026. The company has.

What is Nanobiotix S.A.'s industry? Nanobiotix S.A. (nanobiotix.com) operates in Biotechnology/Oncology. AskCyborg classifies Nanobiotix S.A. under Biotechnology/Oncology in its company registry.

Nanobiotix is a late-stage clinical biotechnology company pioneering the discovery, development, manufacture, and commercialization of disruptive, physics-based nanotherapeutics. Its lead product candidate is NBTXR3, ...

7/ 10Strong

Cyborg Score thesis

Nanobiotix is a physics-based cancer nanotherapy company with differentiated NBTXR3 in partnership with J&J, multiple 2026...

Read the full analyst-debate transcript →
Industry Biotechnology/Oncology
2 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Nanobiotix S.A. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Nanobiotix S.A.

AskCyborg analysts argue the bull and bear cases for Nanobiotix S.A. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Nanobiotix S.A. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Nanobiotix S.A. Overview

Pro stress-test →

Nanobiotix is a late-stage clinical biotechnology company pioneering the discovery, development, manufacture, and commercialization of disruptive, physics-based nanotherapeutics. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. The company has secured strategic partnerships and non-dilutive financing to advance its oncology pipeline.

Strategic Profile

Pro stress-test →

Nanobiotix is engaged in a global licensing agreement with Janssen Pharmaceutica NV, a Johnson & Johnson Company, for the co-development and commercialization of the first-in-class radioenhancer, with the development plan initially focused on cancers of the head, neck, and lungs. The company took a non-dilutive strategic royalty monetization with HCRx, saw continued advancement of the JNJ-1900 (NBTXR3) program with completion of the Phase 3 head and neck cancer study sponsorship transfer to J&J, and its Curadigm Nanoprimer program is rapidly emerging as a long-term growth driver.

Competitive Landscape

Pro stress-test →

Nanobiotix competes in the oncology nanotherapy and radiotherapy enhancement space against emerging biotech competitors. Comparable biotech companies include Inhibrx Biosciences with a market cap of $1.078B and Innate Pharma S.A. with a market cap of $160.738M. The company's unique physics-based approach and J&J partnership provide competitive advantages.

Industry Context

Nanobiotix S.A. operates in Biotechnology/Oncology.

Key facts

Founded: 2003 · Headquarters: Paris, France · Revenue: $10.2M · Market cap: $1.50B

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Nanobiotix S.A..

  • Guggenheim raised their price target on Nanobiotix from $8.00 to $26.00 with a 'buy' rating as of February 6th, 2026.
  • The company has a partnership with Lian Oncology Limited to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand.
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026Nanobiotix announced management participation in multiple March 2026 investor conferences including TD Cowen's Health Care Conference, UBS Biotech Summit, Jefferies Biotech on the Beach, and Leerink's Global Healthcare Conference.
  • November 2025Nanobiotix reported closing of its non-dilutive royalty financing transaction with HCRx with clinical updates from ongoing JNJ-1900 Phase 1 studies in melanoma, lung cancer, pancreatic cancer, and esophageal cancer expected in 2026.
  • +1 moreTrack every material event for Nanobiotix S.A. as it happens. Explore monitoring →
Get alerted when Nanobiotix S.A. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Radiotherapy EnhancementClinical-stage oncology company (Market Cap: $1.078B)→Immunotherapy/OncologyClinical-stage biotech (Market Cap: $160.738M)→

Compare Nanobiotix S.A. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Nanobiotix S.A. operates in Biotechnology/Oncology. See how the rest of the sector scores on the Cyborg framework.

Top companies in Biotechnology by Cyborg Score

Browse Biotechnology/Oncology research →
NEW · MCP server

Ask your AI assistant about Nanobiotix S.A.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Nanobiotix S.A. and its top competitor on Cyborg Score”
“What did Nanobiotix S.A. do this quarter?”
“Is Nanobiotix S.A. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Nanobiotix S.A. do?+
Nanobiotix is a late-stage clinical biotechnology company pioneering the discovery, development, manufacture, and commercialization of disruptive, physics-based nanotherapeutics. Its lead product candidate is NBTXR3, ...
What is Nanobiotix S.A.'s Cyborg Score?+
Nanobiotix S.A. has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Nanobiotix S.A.'s main competitors?+
Named competitors include Radiotherapy Enhancement, Immunotherapy/Oncology. The full competitive landscape is in the AskCyborg report.
How can I get the full Nanobiotix S.A. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Nanobiotix S.A. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Nanobiotix S.A. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

More Biotechnology research

Companies in the same sector and named competitors, ranked by Cyborg Score.

8Abivax SA8Bavarian Nordic A/S8Beam Therapeutics Inc.8CG Oncology, Inc.8Cogent Biosciences, Inc.8COMPASS Pathways plc8CSL Limited8Eckert & Ziegler SE8Krystal Biotech, Inc.8Legend BiotechTop companies in Biotechnology by Cyborg Score